Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition.
Kashiwagi H, Kuwana M, Murata M, Shimada N, Takafuta T, Yamanouchi J, Kato H, Hato T, Tomiyama Y; Committee for Reference Guide for diagnosis of adult ITP Research Team for Coagulopathy and Other Intractable Diseases supported by the Ministry of Health, Labor and Welfare Science Research Grant Project: Research on Health Care Policy for Intractable Diseases. Kashiwagi H, et al. Among authors: shimada n. Int J Hematol. 2024 Jan;119(1):1-13. doi: 10.1007/s12185-023-03672-1. Epub 2023 Nov 13. Int J Hematol. 2024. PMID: 37957517 Free PMC article.
Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Ohhira T, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K. Kubota K, et al. Among authors: shimada n. Lung Cancer. 2020 Mar;141:32-36. doi: 10.1016/j.lungcan.2019.11.009. Epub 2019 Nov 29. Lung Cancer. 2020. PMID: 31931444 Clinical Trial.
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Persano M, et al. Among authors: shimada n. Target Oncol. 2024 Apr 30. doi: 10.1007/s11523-024-01061-0. Online ahead of print. Target Oncol. 2024. PMID: 38689194
Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report.
Xu S, Shukuya T, Shimamura S, Hayashi T, Sato Y, Shiozaki H, Nishioki T, Nishino K, Kato M, Hattori A, Shimada N, Suzuki K, Kitano S, Takahashi K. Xu S, et al. Among authors: shimada n. Transl Lung Cancer Res. 2024 Mar 29;13(3):666-672. doi: 10.21037/tlcr-23-765. Epub 2024 Mar 27. Transl Lung Cancer Res. 2024. PMID: 38601437 Free PMC article.
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, Tani J, Takaguchi K, Atsukawa M, Itobayashi E, Nishimura T, Tsuji K, Tajiri K, Ishikawa T, Yasuda S, Toyoda H, Fukunishi S, Ogawa C, Kakizaki S, Shimada N, Naganuma A, Kawata K, Kosaka H, Kuroda H, Matono T, Yata Y, Ochi H, Tada F, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T; Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group). Ohama H, et al. Among authors: shimada n. Cancer Rep (Hoboken). 2024 Apr;7(4):e2042. doi: 10.1002/cnr2.2042. Cancer Rep (Hoboken). 2024. PMID: 38577725 Free PMC article.
1,329 results